To contentTo navigationTo search

Implantica publishes Interim Report January – March 2023 (Q1)

 | Regulatory

RefluxStop™ - Designed for a Revolution in the Care of Acid Reflux

Significant events in the first quarter of 2023

  • RefluxStop™ is currently being launched in Scandinavia, with Ersta Hospital and Sundsvall Sjukhus in Sweden, the first centers committing to join our registry study.
  • Validated clinical data collection continues for RefluxStop™ with AKH Vienna presenting their results on their first RefluxStop™ patients at the Finnish Gastro Days Congress in Helsinki.
  • The first RefluxStop™ surgeries have been performed in Spain as we continue to prepare for the public tender process.
  • Another major German Reflux Center, Klinikum Aschaffenburg, completed first RefluxStop cases and also signed up for the Registry study.
  • The American Foregut Society (AFS) published a white paper outlining the steps of how acid reflux develops, which further reflects the core RefluxStop™ treatment principles.
  • Ethics Committee approval of the registry study has been achieved in Switzerland with Inselspital Bern and Hirslanden Klinik Beau-Site joining the study.
  • Successfully completed ISO 13485 and MDSAP recertifications.

Significant events after the end of the period

  • The first RefluxStop procedures were performed in Italy at two centers: Ospedale Buon Consiglio Fatebenefratelli in Napoli by Prof. Renzi and IRCCS Ospedale Galeazzi - Sant'Ambrogio in Milan by Prof. Bona, joined by Prof. Bonavina, president of the European Foregut Society.
  • The 100th RefluxStop procedure was completed in a single center at Klinikum Friedrichshafen, a leading anti-reflux Center of Excellence in Germany.
  • Followed by approval in Switzerland, RefluxStop Registry Study (ReStore) has now also been approved in Germany.
  • Dr. med. Borbély from InselSpital, Switzerland’s largest University hospital, presented his successful RefluxStop 3-year results at SAGES (Society of American Gastrointestinal and Endoscopic Surgeons) conference in Montreal, Canada. He concluded that the excellent data from the CE mark study could be replicated in a real-world setting.
  • The RefluxStop cost-effectiveness analysis comparing RefluxStop™ against PPIs, Fundoplication and Magnetic Sphincter Augmentation results are now published in the peer-reviewed Journal of Medical Economics well known for covering economic assessments of novel therapeutic and medical device interventions.
  • Implantica has been selected as one of 50 Admired Companies to Watch 2023 by CIO Bulletin.

Financial summary first quarter 2023

  • Net sales increased 55% to TEUR 307 (198).
  • Adjusted gross margin amounted to 95% (95%).
  • Operating loss (EBIT) increased to TEUR 4,870 (4,411).
  • Loss after tax amounted to TEUR 4,758 (4,888).
  • Basic and diluted loss per Class A share amounted to EUR 0.07 (0.07).
  • Cash as at the end of the period amounted to MEUR 102.3.

Implantica will hold a telephone conference on May 12 at 15:00 CEST.

Implantica will hold a teleconference with Peter Forsell (CEO), Andreas Öhrnberg (CFO) and Nicole Pehrsson (Chief Corporate Affairs Officer & Investor Relations). Please see dial-in details below to join the conference:

Dial-in number (toll free)

  • SE: +46 850 516 386
  • UK: +44 203 198 4884
  • US: +1 412 317 6300

(Pin code: 9354290#)

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB,

The information was sent for publication, through the agency of the contact person set out above, on May 12, 2023 at 08:00 a.m. (CEST).

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information.


  • logo_transparent_1 (8).png